egl-4 modulates electroconvulsive seizure duration in C. elegans

Invertebrate Neuroscience : in
Monica G RisleyKen Dawson-Scully

Abstract

Increased neuronal excitability causes seizures with debilitating symptoms. Effective and noninvasive treatments are limited for easing symptoms, partially due to the complexity of the disorder and lack of knowledge of specific molecular faults. An unexplored, novel target for seizure therapeutics is the cGMP/protein kinase G (PKG) pathway, which targets downstream K+ channels, a mechanism similar to Retigabine, a recently FDA-approved antiepileptic drug. Our results demonstrate that increased PKG activity decreased seizure duration in C. elegans utilizing a recently developed electroconvulsive seizure assay. While the fly is a well-established seizure model, C. elegans are an ideal yet unexploited model which easily uptakes drugs and can be utilized for high-throughput screens. In this study, we show that treating the worms with either a potassium channel opener, Retigabine or published pharmaceuticals that increase PKG activity, significantly reduces seizure recovery times. Our results suggest that PKG signaling modulates downstream K+ channel conductance to control seizure recovery time in C. elegans. Hence, we provide powerful evidence, suggesting that pharmacological manipulation of the PKG signaling cascade may control se...Continue Reading

References

Feb 11, 1994·Science·M ChalfieD C Prasher
Dec 10, 1996·Proceedings of the National Academy of Sciences of the United States of America·D LevitanI Greenwald
Feb 26, 2003·Neurobiology of Aging·Christopher D LinkBarbara G Sahagan
Jul 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·Frederic MeryTadeusz J Kawecki
Jan 10, 2008·Proceedings of the National Academy of Sciences of the United States of America·Shusei HamamichiGuy A Caldwell
Jun 29, 2010·The Journal of Experimental Biology·K Dawson-ScullyM B Sokolowski
Jan 1, 2010·Clinical Pharmacology : Advances and Applications·Vincenzo BarreseMaurizio Taglialatela
Nov 12, 1986·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·J G WhiteS Brenner
May 11, 2012·Neurology·M J BrodieP Kwan
Jul 23, 2013·PLoS Genetics·Michelle C KrzyzanowskiDenise M Ferkey
Mar 1, 2014·Korean journal of pediatrics·June-Bum Kim
Aug 22, 2014·Neuropsychiatric Disease and Treatment·Jerzy P SzaflarskiLaura E Dreer
Jan 28, 2015·Journal of Epilepsy Research·Sang Kun Lee
Jan 29, 2016·Journal of Epilepsy Research·L K FriedmanS S Ali
Sep 27, 2016·PloS One·Monica G RisleyKen Dawson-Scully
Apr 27, 2017·Cell Reports·Karla J OppermanBrock Grill

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
protein folding

Software Mentioned

SigmaPlot

Related Concepts

Related Feeds

Antiparasitics

Antiparasitics are medications which are indicated for the treatment of parasitic diseases. Discover the latest research on antiparasitics here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Anthelmintics (ASM)

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Related Papers

Current Clinical Pharmacology
Debra J Tompson, Christopher S Crean
Nihon rinsho. Japanese journal of clinical medicine
K Fukuo, T Ogihara
© 2022 Meta ULC. All rights reserved